Back to top
more

Zoetis (ZTS)

(Real Time Quote from BATS)

$172.77 USD

172.77
1,412,360

+2.40 (1.41%)

Updated Nov 7, 2024 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks News

Zoetis (ZTS) Just Overtook the 20-Day Moving Average

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.

Zoetis (ZTS) Q1 Earnings and Revenues Beat Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of 21.15% and 7.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?

Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases first-quarter 2021 results.

Sheraz Mian headshot

Top Stock Reports for Apple, Alphabet & BlackRock

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Alphabet (GOOGL), and BlackRock (BLK).

Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AstraZeneca (AZN) Gets FTC Clearance for Alexion Acquisition

AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.

Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU

The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.

FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag

The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.

Sanofi (SNY) Acquires Tidal to Aid mRNA-Based Research Platform

Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.

The Zacks Analyst Blog Highlights: Apple, Alibaba Group, AT&T, Intuitive Surgical and Zoetis

The Zacks Analyst Blog Highlights: Apple, Alibaba Group, AT&T, Intuitive Surgical and Zoetis

Mark Vickery headshot

Top Stock Reports for Apple, Alibaba & AT&T

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Alibaba Group Holding Limited (BABA) and AT&T Inc. (T).

Pfizer (PFE) Gets Unfavorable Votes from FDA Panel for Tanezumab

Pfizer (PFE) and Eli Lilly receive FDA Joint Advisory Committee's vote results for tanezumab being developed for treating osteoarthritis pain. The committee voted 1 in favor and 19 against tanezumab.

Novartis (NVS) Posts Positive Data From Prostate Cancer Study

Novartis (NVS) reports positive data from the phase III VISION study evaluating its radioligand therapy, 177Lu-PSMA-617, in patients with advanced prostate cancer.

Zoetis (ZTS) Down 7.5% Since Last Earnings Report: Can It Rebound?

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Translate (TBIO) Down on Unsatisfactory CF Drug Study Results

Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.

USNA vs. ZTS: Which Stock Should Value Investors Buy Now?

USNA vs. ZTS: Which Stock Is the Better Value Option?

Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y

Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.

Roche (RHHBY) Inks Deal to Acquire GenMark Diagnostics for $1.8B

Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.

The Zacks Analyst Blog Highlights: Tapestry, Ulta Beauty, Synchrony Financial, CDW Corp and Zoetis

The Zacks Analyst Blog Highlights: Tapestry, Ulta Beauty, Synchrony Financial, CDW Corp and Zoetis

Sweta Killa headshot

5 Top-Ranked Stocks Backed by Women Power

We have highlighted some top-ranked stocks from the S&P 500 that are headed by female CEOs and have massive upside potential in the coming years.

ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss

ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.